Nifty Gains Concentrate in Defensives and Banks

Kotak Mahindra Bank led the small group of outperformers with a 7% rise, helped by renewed faith in large private banks after Macquarie upgraded the stock to Outperform. That fits the broader defensive trade in financials: lenders with stronger franchises and cleaner growth paths tend to attract capital when valuations compress and market breadth deteriorates.

Dr Reddy’s Laboratories gained 5%, showing how pharma can act as a shelter when macro risks rise. The stock also had company-specific support, with Nomura pointing to biologics milestones and Citi shifting to Buy from Sell after more than three years of caution. For investors, the important point is that the rally was not just about defensiveness; it was about a rerating as visibility improved on future launches and regulatory outcomes.

Eternal, parent of Zomato and Blinkit, rose 4% as the market continued to look through near-term earnings volatility and focus on long-term scale in food delivery and quick commerce. Goldman Sachs raised its target price and said the company could reach $1 billion in EBITDA by FY29, reflecting a willingness to pay for platform growth even in a risk-off tape. That makes Eternal one of the few high-beta names still getting the benefit of strategic conviction.

Adani Ports and Coal India were the other notable gainers, up 2% each, highlighting demand for operationally resilient, cash-rich businesses. Adani Ports benefited from record August cargo volumes of 50 million metric tonnes, while Coal India drew support from a fifth straight month of volume growth and the appeal of dividends in a falling market. In both cases, the market favored hard assets and steady cash flows over cyclical uncertainty.

The near-flat performance of Axis Bank and Bharat Electronics, both down only 1%, completes the picture. Axis reported strong business growth, while Bharat Electronics remained supported by defence spending and a large order book. Their relative resilience suggests investors were still willing to own growth, but only when it came with earnings momentum or policy-backed visibility.

The message for investors is that India’s recent selloff has been a test of quality, not just valuation. If foreign outflows persist and oil stays elevated, the market is likely to continue rewarding banks, pharma, defence, ports and dividend-heavy names while punishing exposed high-beta pockets. A broader rebound will probably require either a turn in global rates and crude or evidence that domestic earnings can reaccelerate enough to draw back foreign capital.